# CONC (Conectisys Corporation) - SEC EDGAR Financial Statements

> Conectisys Corporation reported $0 in revenue and a net loss of $9.0K for the fiscal year ended September 30, 2021.

- Canonical: https://convexityos.com/fundamentals/CONC
- Markdown: https://convexityos.com/fundamentals/CONC.md
- SEC CIK: 0000790273
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:13 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000790273&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2021 | $0 | Sep 30, 2021 |
| Operating Income | FY 2021 | -$4.3K | Operating profit |
| Net Income | FY 2021 | -$9.0K | GAAP bottom line |
| Diluted EPS | FY 2021 | -$0.01 | Split-adjusted |
| Free Cash Flow | FY 2021 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | -- | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2021 | FY 2020 |
| --- | --- | --- |
| **Revenue** | $0 | $0 |
| Cost of Revenue | $0 | $0 |
| **Gross Profit** | $0 | $0 |
| Total Operating Expenses | $4.3K | $5.9K |
| **Operating Income** | -$4.3K | -$5.9K |
| Income Tax Expense | $0 | $0 |
| **Net Income** | -$4.3K | -$5.9K |
| Basic EPS | $0.00 | -$0.03 |
| **Diluted EPS** | $0.00 | -$0.03 |
| Basic Shares Outstanding | 888.6K | 215.7K |
| Diluted Shares Outstanding | 888.6K | 215.7K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | -- | $0 | $0 | $0 | -- |
| Cost of Revenue | $0 | $0 | $0 | -- | $0 | $0 | $0 | -- |
| **Gross Profit** | $0 | $0 | $0 | -- | $0 | $0 | $0 | -- |
| **Net Income** | -$2.2K | -$2.2K | -$2.2K | -$2.2K | -$1.4K | -$428 | -$1.1K | -$1.1K |
| Basic EPS | $0.00 | $0.00 | $0.00 | -- | $0.00 | $0.00 | $0.00 | -- |
| **Diluted EPS** | $0.00 | $0.00 | $0.00 | -- | $0.00 | $0.00 | $0.00 | -- |
| Basic Shares Outstanding | 1.4M | 1.4M | 1.4M | -- | 1.4M | 1.4M | 1.4M | -- |
| Diluted Shares Outstanding | 1.4M | 1.4M | 1.4M | -- | 1.4M | 1.4M | 1.4M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2021 | FY 2020 |
| --- | --- | --- |
| Cash & Cash Equivalents | $0 | $0 |
| **Cash & Short-Term Investments** | $0 | $0 |
| **Total Current Assets** | $0 | $0 |
| Property, Plant & Equipment, Net | $0 | $0 |
| **Total Non-Current Assets** | $0 | $0 |
| **Total Assets** | $0 | $0 |
| **Total Current Liabilities** | $32K | $27K |
| **Total Non-Current Liabilities** | $0 | $0 |
| **Total Liabilities** | $32K | $27K |
| Common Stock | $32.25M | $32.25M |
| Retained Earnings | -$32.28M | -$32.27M |
| Accumulated Other Comp. Income | $0 | $0 |
| **Total Stockholders' Equity** | -$32K | -$27K |
| Total Equity | -$32K | -$27K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Total Current Assets** | $0 | $0 | $0 | $0 | $7.0K | $8.4K | $8.8K | $0 |
| Property, Plant & Equipment, Net | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Non-Current Assets** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Assets** | $0 | $0 | $0 | $0 | $7.0K | $8.4K | $8.8K | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $5.0K | $5.0K | $5.0K | $25K |
| Other Current Liabilities | $7.0K | -- | -- | $287 | -- | -- | -- | -- |
| **Total Current Liabilities** | $7.0K | $4.8K | $2.5K | $287 | $5.0K | $5.0K | $5.0K | $54K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $7.0K | $4.8K | $2.5K | $287 | $5.0K | $5.0K | $5.0K | $54K |
| Common Stock | -- | $3.8K | $3.8K | $3.8K | $3.8K | $3.8K | $3.8K | $32.25M |
| Retained Earnings | -$11K | -$8.6K | -$6.4K | -$4.1K | -$1.9K | -$428 | $0 | -$32.30M |
| **Total Stockholders' Equity** | -$7.0K | -$4.8K | -$2.5K | -$287 | $2.0K | $3.4K | -$55K | -$54K |
| Total Equity | -$7.0K | -$4.8K | -$2.5K | -$287 | $2.0K | $3.4K | -$55K | -$54K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2021 | FY 2020 |
| --- | --- | --- |
| Net Income | -$4.3K | -$5.9K |
| **Operating Cash Flow** | -$100 | -- |
| **Investing Cash Flow** | $100 | $0 |
| **Financing Cash Flow** | $0 | $0 |
| **Net Change in Cash** | $0 | $0 |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.2K | -$2.2K | -$2.2K | -$2.2K | -$1.4K | -$428 | -$1.1K | -$1.1K |
| Change in Payables | $0 | $0 | $0 | -- | $0 | $0 | $0 | -- |
| **Operating Cash Flow** | $0 | $0 | $0 | -- | -$1.4K | -$428 | $0 | -- |
| **Investing Cash Flow** | $0 | $0 | $0 | -- | $0 | $0 | $0 | -- |
| Common Stock Issued | $0 | $0 | $0 | -- | $0 | $8.8K | $0 | -- |
| **Financing Cash Flow** | $0 | $0 | $0 | -- | $0 | $8.8K | $0 | -- |
| **Net Change in Cash** | $0 | $0 | $0 | -- | -$1.4K | $8.4K | $0 | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2021 | FY 2020 |
| --- | --- | --- |
| Current Ratio | 0.00x | 0.00x |
| Quick Ratio | 0.00x | 0.00x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -- | -- | -- | 256.9% | -- | -- |
| Return on Assets (ROA) | -- | -- | -- | -- | -- | 103.8% | 30.9% | -- |
| Current Ratio | 0.00x | 0.00x | 0.00x | 0.00x | 1.39x | 1.68x | 1.76x | 1.76x |
| **Net Income Growth (YoY)** | -- | -- | -- | -- | -112.6% | -- | -- | -- |

## Related Companies

[COBA (Chilean Cobalt Corp.)](https://convexityos.com/fundamentals/COBA), [CRBP (Corbus Pharmaceuticals Holdings, Inc.)](https://convexityos.com/fundamentals/CRBP), [CNTA (Centessa Pharmaceuticals PLC)](https://convexityos.com/fundamentals/CNTA), [CRCE (Circle Energy, Inc./NV)](https://convexityos.com/fundamentals/CRCE), [CNBX (Cnbx Pharmaceuticals Inc.)](https://convexityos.com/fundamentals/CNBX), [CTNM (Contineum Therapeutics, Inc.)](https://convexityos.com/fundamentals/CTNM), [CMPX (Compass Therapeutics, Inc.)](https://convexityos.com/fundamentals/CMPX), [CVAT (Cavitation Technologies, Inc.)](https://convexityos.com/fundamentals/CVAT)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
